Should You Buy ResMed Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, ResMed Inc. (RMD) ranks in the top tier of our coverage universe with a Quality of Company score of 10.0/10. Trading at a market price of $198.99, this high-quality profile requires careful comparison against our 13 intrinsic value models.
The short answer: 2 of 13 CirclFi valuation models project upside for ResMed Inc. (RMD) at $198.99 — the model consensus leans bearish, with a Quality Score of 10.0/10 and Value-Trap risk of 12/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
Investment Thesis
The Bull Case
Target: $231.61 (+16.4% upside)
- According to the CirclFi Quality of Company (QOC) framework, ResMed Inc.'s quality score of 10.0/10 demonstrates the operational excellence that historically correlates with long-term shareholder value creation.
- According to the CirclFi Deep Alpha Valuation Engine, the First Chicago model targets a fair value of $231.61 (+16.4%), anchoring the bull case with a methodology that evaluates base, bull, and bear scenarios simultaneously.
The Bear Case
Target: $18.93 (-90.5%)
- According to the CirclFi Deep Alpha Valuation Engine, the Dynamic NAV model sees the stock as overvalued with a fair value of $18.93 (-90.5%), suggesting that the market price embeds overly optimistic growth assumptions.
- According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +106.9% spread between the most bullish and bearish models, signaling elevated analytical uncertainty.
The Bottom Line
Caution dominates our read on ResMed Inc. at $198.99. 9 of 13 models see limited upside or outright downside, with the composite fair value at $131.82 (-33.8%). Quality at 10.0/10 provides some fundamental cushion. Current holders should re-evaluate their thesis; new buyers should demand a wider margin of safety.
These are quantitative model outputs, not investment recommendations. ResMed Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
Frequently Asked Questions
Should I buy RMD stock right now?
Based on CirclFi's multi-model analysis, 2 of 13 models see upside for RMD at $198.99. The models are divided, which means the investment case depends heavily on your assumptions about ResMed Inc.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in ResMed Inc.?
Key risks include: wide model disagreement (1124% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Instruments & Supplies companies. Always diversify and consult a financial advisor.
How does RMD compare to its competitors?
Among Medical Instruments & Supplies peers, RMD holds a Quality Score of 10.0/10. Comparable companies include WST (QOC 9.9), LMAT (QOC 9.8), ISRG (QOC 9.5). The relative ranking helps investors identify whether RMD offers better fundamental quality than alternatives in the same sector.
Is RMD a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. RMD's Quality Score of 10.0/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy RMD at?
CirclFi does not provide target buy prices or price alerts. However, our 13 active models produce fair value estimates ranging from $18.93 to $231.61. At $198.99, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for RMD.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad